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INTRODUCTION
During the past decade, the therapy of chronic myeloid leukemia (CML) has experienced unprecedented improvements of response and survival. 1 Tyrosine kinase inhibitors (TKIs) allow a much faster reduction of BCR-ABL transcript levels than previously available drug therapy, 2 which is associated with a lower rate of progression and an improvement of survival. Still, some patients continue to respond suboptimally 3 or become resistant and require alternative treatment 4 with second-generation TKIs 5 or early stem cell transplantation. 6 Early prediction of suboptimal response or failure would benefit this group of patients. 7 Prognostic scores to estimate patients' outcome risk at diagnosis have been established for busulfan or interferon alpha (IFN)-treated patients. 4, 8, 9 The new 'EUTOS Score' combining baseline spleen size and peripheral blood basophils to predict the achievement of complete cytogenetic remission (CCyR) and progression-free survival (PFS) is now available from imatinibtreated patients. 10 A powerful prediction has also evolved from time-dependent variables describing response to therapy. Hematologic, cytogenetic and molecular criteria are used to define optimal response, suboptimal response and treatment failure at 3, 6, 12 1 III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany; and 18 months or later after the start of front-line treatment with imatinib. 4, 11 Treatment failure at these time points has been shown to be closely related to PFS and overall survival (OS). 12 CCyR has been established as the gold standard for outcome prediction within the International Randomized Study of Interferon and STI571 (IRIS). 13 More recently, molecular response determined by BCR-ABL transcript levels according to the international scale (BCR-ABL IS ) at defined time points has been used as a predictive marker. [14] [15] [16] So far, results of the German CML Study IV showed a superior OS of patients achieving p1% BCR-ABL IS at 12 months of treatment, which was associated with a 3-year survival of 98% as compared with 93% in the 41% group. 17 The aim of the present study was to clarify the relation between early kinetics of molecular and cytogenetic response and the risk for disease progression and death in patients receiving imatinib treatment. Analyzing patients of the German CML Study IV, we report here molecular and cytogenetic milestones to be achieved at 3 and 6 months of treatment to ensure the most favorable outcome and effective TKI treatment.
PATIENTS AND METHODS

Study design
The randomized CML Study IV compares monotherapy of imatinib 400 mg/d versus imatinib 400 mg/d þ IFN versus imatinib 400 mg/d þ low-dose cytarabine versus imatinib 400 mg/d after failure of IFN versus imatinib 800 mg/d. Assignment to the study arms using imatinib in combination with cytarabine and imatinib after failure of IFN was terminated in 2005. 17 Cytogenetic and molecular analyses Cytogenetic response was determined by conventional metaphase analyses with standard G-banding or fluorescence R-banding techniques after shortterm culture. At least 20 bone marrow cell metaphases were evaluated. The expressions of BCR-ABL and total ABL were determined by quantitative reverse transcriptase polymerase chain reaction from peripheral blood samples 14 and standardized according to the international scale (BCR-ABL IS ). [18] [19] [20] Only patients expressing typical BCR-ABL transcripts (b2a2, b3a2 or both b2a2 and b3a2) and monitored in standardized labs were considered. Patients with atypical transcripts (e1a2, n ¼ 3; b2a3, n ¼ 3; b3a3, n ¼ 3; b2a3 and b3a3, n ¼ 2; e19a2, n ¼ 10), unknown transcripts or monitored in nonstandardized labs (n ¼ 52) were excluded from the analysis.
Definitions of treatment response PFS was defined by absence of accelerated phase, blast crisis and death from any reason; OS by absence of death from any reason. Molecular and cytogenetic remissions were defined according to European LeukemiaNet criteria. 4 Major molecular remission (MMR) was defined as a 3-log reduction of BCR-ABL transcript levels, corresponding to p0.1% BCR-ABL IS .
Statistical analysis
Landmark analyses were performed according to molecular and cytogenetic response at 3 and 6 months. Patients with a response assessment within an interval of 1.5-4.5 or 4.5-7.5 months were considered evaluable for the respective analysis. Probabilities of OS and PFS were calculated by the Kaplan-Meier method and compared by the log-rank statistic. Additionally, hazard ratios were estimated from a proportional hazards model. Cumulative incidences were calculated under consideration of competing risks 21 defined by accelerated phase, blast crisis and death. Comparisons between cumulative incidences were performed by the Gray test. For the analysis of contingency tables, w 2 test was used. Analyses were according to intention-to-treat principle. All patients randomized to primary imatinib-based treatment and with available response data were analyzed whether they had received imatinib or not. Level of significance was 0.05. Owing to the exploratory character of this work, all P-values have to be interpreted descriptively, in particular as no adjustment of P-values or significance levels was applied. All calculations were performed with the SAS software Version 9.1.3 (SAS Institute, Cary, NC, USA).
Ethics
The protocol followed the Declaration of Helsinki and was approved by the ethics committee of the Medizinische Fakultät Mannheim der Universität Heidelberg and by local ethics committees of participating centers. Written informed consent was obtained from all patients before they entered the study.
RESULTS
Patients and outcome
From July 2002 to April 2010, a total of 1440 patients were randomly assigned to the study arms of CML Study IV; 1303 imatinib-treated patients were investigated (Supplementary Figure 1) . In all, 1223 patients were evaluable for molecular and 1239 patients for cytogenetic analyses. Data entry was closed on June 15, 2011. Patients' characteristics at diagnosis and assignment to treatment arms are summarized in Supplementary  Table 1 . A multivariate analysis revealed no significant impact of the particular treatment arm on PFS and OS in addition to the early response markers investigated. Therefore, a pooled sample of patients on imatinib-based treatment was analyzed in a univariate analysis. Median age of patients evaluable for molecular analysis was 52 years (range 16-85), 39% of patients were female. The median follow-up was 57.8 months (Supplementary Table 1 ). In total, disease progression was observed in 131 patients (9.1%), 108 patients died (7.5%).
Within the first 4.5 months of treatment, disease progression (including death) was observed in 9 patients, 2 patients died. Four of the surviving patients had a molecular assessment, 2 had a cytogenetic analysis at 3 months and could therefore be included into OS but not into PFS landmark analysis. Within the first 7.5 months of treatment, disease progression was observed in 19 patients, 4 patients died. Six of the surviving patients had a molecular assessment, 3 had a cytogenetic analysis at 6 months.
PFS and OS according to molecular response at 3 months At 3 months, molecular assessment was performed in 692 patients. The median BCR-ABL IS was 2.7% (0-100). The 10% and 1% BCR-ABL IS cutoffs were chosen for an exploratory landmark analysis. BCR-ABL IS p1% was observed in 218 patients (31%), 41-10% BCR-ABL IS in 283 patients (41%) and 410% BCR-ABL IS in 191 patients (28%). Survival of the BCR-ABL IS 410% group was inferior as compared with the neighboring 41-10% group (P ¼ 0.037 for PFS, P ¼ 0.012 for OS) and as compared with the p1% group (P ¼ 0.002 for PFS, Figure 1a ; P ¼ 0.004 for OS, Figure 1b ). By contrast, the p1% group had no significant advantage as compared with the neighboring 41-10% group. The 5-year OS was 97% for p1% BCR-ABL IS , 94% for 41-10% BCR-ABL IS and 87% for 410% BCR-ABL IS at 3 months of treatment (Table 1) .
PFS and OS according to cytogenetic response at 3 months At 3 months, cytogenetic analysis was performed in 460 patients. The median proportion of Philadelphia chromosome-positive metaphases (Ph þ ) was 8% (0-100). The 65%, 35% and 0% Ph þ cutoffs were chosen for an exploratory landmark analysis. Ph þ p35% was observed in 336 patients (73%), 435-65% Ph þ in 39 patients (9%) and 465% Ph þ in 85 patients (18%). Survival of the Ph þ p35% group was superior as compared with the 435% group (P ¼ 0.016 for PFS, P ¼ 0.036 for OS, Figures 1c and  d) . Survival of the Ph þ p65% group was superior as compared with the 465% group (P ¼ 0.002 for PFS, P ¼ 0.010 for OS). The 5-year OS was 95% for p35% Ph þ , 94% for 435-65% Ph þ and 85% for 465% Ph þ at 3 months of treatment (Table 2) .
Cumulative incidence of CCyR and major molecular remission according to molecular response at 3 months Beyond 3 months, cytogenetic follow-up was available for 583 patients; molecular follow-up was available for 625 patients. Correlation of 3-month molecular response with baseline risk stratification according to EUTOS score A 3-group stratification according to molecular and cytogenetic response at 3 months was significantly associated with baseline risk according to EUTOS score (Po0.001 for molecular response, P ¼ 0.035 for cytogenetic response, Supplementary Table 2 ).
PSF and OS according to molecular response at 6 months At 6 months, molecular assessment was performed in 789 patients. The median BCR-ABL IS was 0.37% (0-100). BCR-ABL IS p1% was observed in 498 patients (63%), 41-10% BCR-ABL IS in 196 patients (25%) and 410% BCR-ABL IS in 95 patients (12%). Survival of the BCR-ABL IS p1% group was superior as compared with the neighboring 41-10% group (P ¼ 0.006 for PFS, P ¼ 0.002 for OS) and the 410% group (Po0.001 for PFS, Po0.001 for OS). In contrast, the 41-10% group had no significant advantage as compared with the neighboring 410% group (Figure 2a and b) . The 5-year OS was 97% for p1% BCR-ABL IS , 90% for 41-10% BCR-ABL IS and 88% for 410% BCR-ABL IS at 6 months of treatment (Table 1) .
PFS and OS according to cytogenetic response at 6 months At 6 months, cytogenetic analysis was performed in 482 patients. The median Ph þ was 0% (0-100). Ph þ of 0% was observed in 320 patients (66%), 40-35% Ph þ in 109 patients (23%), 435-65% Ph þ in 19 patients (4%) and 465% Ph þ in 34 patients (7%). Survival of the Ph þ 0% group was superior as compared with the 40% group (P ¼ 0.014 for PFS, P ¼ 0.015 for OS, Figure 2c and d) . The 5-year OS was 97% for 0% Ph þ , 95% for 40-35% Ph þ , 86% for 435-65% Ph þ and 80% for 465% Ph þ at 6 months of treatment ( Table 2) .
Validation of the prognostic significance of 3-month molecular response An independent sample of 174 patients treated with imatinib within the International Randomized Study of Interferon and STI571 22 was used to validate the prognostic significance of 3-month molecular response. BCR-ABL IS p1% was observed in 64 patients (37%), 41-10% BCR-ABL IS in 67 patients (38%) and 410% BCR-ABL IS in 43 patients (25%). In agreement with our results, OS of the BCR-ABL IS 410% group was inferior as compared with the neighboring 41-10% group (P ¼ 0.015) and as compared with the p1% group. As in our sample, the p1% group had no significant advantage as compared with the neighboring 41-10% group. The 8-year OS was 92% for p1% BCR-ABL IS , 93% for 41-10% BCR-ABL IS and 81% for 410% BCR-ABL IS .
DISCUSSION
The approval of second-generation TKIs for frontline treatment of CML gave rise to a vivid debate not only concerning the standard of care for newly diagnosed patients, 23 but also regarding the question as to when to switch to these drugs in case of inferior response to imatinib. Treatment intervention might be warranted as soon as inferior outcome is predictable and therefore early landmarks are needed. Abbreviations: CI, 95% confidence interval; Ph þ , proportion of Philadelphia chromosome positive metaphases; pts, number of patients; 5Y-OS, 5-year overall survival.
Early predictors of response in CML B Hanfstein et al
Molecular and cytogenetic response levels at the first assessment under imatinib treatment are significantly associated with long-term PFS and OS. At 3 months of treatment, 28% of patients failed to achieve the 10% BCR-ABL IS level and had a 5-year OS of only 87%. Significantly better survival rates were observed in patients with 41-10% BCR-ABL IS and p1% BCR-ABL IS (Figure 1b ). No significant difference was observed when the 41-10% and the p1% groups were compared. For this reason, the 10% BCR-ABL IS cutoff was chosen as relevant landmark to define a high-risk group irrespective of the fact that the p1% group had an even better 5-year OS.
The 5-year OS of the p1% group was 97.2%. A similar survival rate (97.7% at six years) was reported for patients with CCyR at 2 years of treatment. In this group, survival was not significantly different from the general population and the majority of patients died of causes unrelated to CML. 24 This gives some weight to the safe haven concept, which provides a landmark indicating a minimal risk of relapse and might already be applied in an early phase of treatment.
Regarding cytogenetic response, 27% of patients failed to achieve major cytogenetic response (MCyR, p35% Ph þ ) at 3 months and had a 5-year OS of 87% (Figure 1d ). It is striking that these proportions are almost congruent when compared with the molecular high-risk definition of 410% BCR-ABL IS (27% vs 28% of patients, 87% 5-year OS in both cases). This finding might corroborate from a prognostic view the equivalence of the 10% BCR-ABL transcript level and the 35% Ph þ level, which has been suggested before. 25 At 3 months, 73% of patients achieved MCyR and had a 5-year OS of 95%. This was significantly better as compared with the group without MCyR, which for this reason constitutes a high-risk group.
At 6 months of treatment, the 1% BCR-ABL IS landmark should be used to define a high-risk group owing to the fact that OS of the p1% group differed significantly as compared with the 41-10% group, whereas the 41-10% group had no significant benefit as compared with the 410% group (Figure 2b) . BCR-ABL IS 41% was observed in 37% of patients, which was associated with a 5-year OS of only 89%. Survival analysis according to 6-month response again revealed a close relationship between molecular and cytogenetic landmarks: 34% of patients failed to achieve CCyR, which was associated with a 5-year OS of 91%. The similarity of proportions (37% for 41% BCR-ABL IS , 34% for less than CCyR) and 5-year OS rates (89% vs 91%) indicates a prognostic equivalence of 1% BCR-ABL IS and CCyR. Moreover, the achievement of CCyR predicts the best outcome of the significant cutoffs explored (Table 2 ) and should therefore be chosen to guide clinical decision making.
These results follow earlier attempts to use hematological, cytogenetic and molecular analyses for the prediction of outcome. [26] [27] [28] Our group has determined a BCR-ABL/ABL ratio o20% at 2 months as a predictor of MCyR in patients treated with imatinib after failure to IFN. 27 Gold standard remained CCyR by 12 or 18 months, which was shown to predict superior PFS and OS. 4 Our CML Study IV data revealed the 1% BCR-ABL IS cutoff at 12 months to predict PFS and OS so far. 17 An evaluation of International Randomized Study of Interferon and STI571 data by Hughes et al. 22 associated 10% BCR-ABL IS at 6 months and 1% BCR-ABL IS at 12 months with better event-free survival and PFS. According to our data, 1% and 10% BCR-ABL IS are predictive at 6 months with the 1% cutoff including more high-risk patients (Table 1) .
The 3-month time point has been used for prediction of survival already in the interferon era. Mahon et al. 26 showed that the achievement of a complete hematological response (CHR) at 3 months is predictive for cytogenetic response and OS. Under imatinib treatment, the lack of CHR at 3 months was associated with a low rate of subsequent CCyR and inferior 5-year PFS and OS. 29 The failure to reach CHR by 3 months is considered as imatinib failure by the 2009 ELN management recommendations. 4 Our first report on the predictive value of molecular response at 3 months 30 was confirmed by others. 16, 31 A recent analysis of 282 patients by Marin et al. 16 defined a BCR-ABL transcript level of 9.84% at 3 months and 1.67% at 6 months as the best cutoff levels to predict OS. Thereby the 3-month value was the strongest predictor, later milestones contributed no additional information. At 3 months, 68 patients failed to achieve p9.84% corresponding to 24% of patients. This is about the same proportion as observed in our sample using the 10% cutoff (28% of patients). An 8-year OS of 57% was observed in the 49.84% group, which is considerably lower than the 5-year OS of 87% in our group and may not only be explained by the longer follow-up. It is striking that an 8-year complete molecular remission (CMR) rate of only 1.5% is reported for patients with 3-month BCR-ABL transcript levels 40.61%, whereas 84% achieve CMR by 8 years in the o0.61% group. 16 Jabbour et al. 32 reported the prognostic significance of 6-and 12-month CCyR for event-free survival and OS. As in our analysis (Table 2 ), CCyR at 3 months did not significantly predict OS but was predictive for event-free survival. A 3-year OS of patients under imatinib or second-generation TKI with CCyR at 6 months was reported as 99% vs 90% in the group without CCyR. This is in agreement with our results concerning 5-year OS according to 6-month CCyR (97% vs 91%, Table 2 ).
The synopsis of these results provides strong evidence for the prognostic significance of early molecular and cytogenetic response landmarks. The question whether an inferior response at 3 months should trigger treatment revision in a considerable proportion of patients may be discussed on the basis of data presented here. Owing to their slow response, about one-fourth of patients were declared high-risk patients at 3 months according to our results (27% with 410% BCR-ABL IS , 28% with 435% Ph þ ), and those reported by Marin et al. 16 (24% with 49.84% BCR-ABL transcript level). About the same proportion (25% with 410% BCR-ABL IS ) was observed in the International Randomized Study of Interferon and STI571 sample. Survival is clearly inferior in all of these groups.
Whether the inferior susceptibility to the effects of ABL kinase inhibition in the group of slow responders might be overcome by the early use of second-generation TKIs is up for debate. The distinct biological characteristics of slow responders might be heterogeneous, and it has been assumed that second-line TKIs may have only partial success. 16 Changing treatment to second line after only 3 months is unusual but may be justified by a hit hard and early rationale to eliminate the BCR-ABL-positive clone as early and effectively as possible. Therefore, a switch to a more efficacious treatment should be recommended for the group of high-risk patients at 3 months.
